Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/ACTRN12622000999730
ACTRN12622000999730Recruiting未知

A Prospective Study to Evaluate the Safety and Feasibility of using the Closed Loop Medical Sacral Nerve Stimulation System in the treatment of symptoms of Overactive Bladder

Closed Loop Medical Pty Ltd0 sites25 target enrollmentStarted: July 15, 2022Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
未知
Status
Recruiting
Sponsor
Enrollment
25
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Non-randomised trial
Primary Purpose
Treatment
Masking
Open (masking not used)

Eligibility Criteria

Ages
18 Years to o limit (—)
Sex
All

Inclusion Criteria

  • •Participants in this study must meet all of the following inclusion criteria, as determined by the Investigator:
  • •1. Participant has a diagnosis of chronic OAB (> 12 months) and documented evidence from a 3-day bladder diary of 4 involuntary leaks associated with urgency during the 3-day period.
  • •2. Participant has tried and failed one or more conservative therapies (e.g. drug therapy, diet/lifestyle modification, pelvic floor physiotherapy (including bladder re-training), biofeedback, osteopathy, acupuncture) and is suitable to proceed to more advanced therapies, as determined by the Investigator.
  • •3. Participant has been approved by the Investigator to undergo an SNS procedure.
  • •4. Participant is an appropriate candidate for the surgical procedures required in this study based on the clinical judgment of the Investigator.
  • •5. Participant is on a stable dose (no new, discontinued, or changes in dose) of all medication to treat their OAB for at least 4 weeks prior to the implantation.
  • •6. Participant is male or female, 18 years of age or older
  • •7. Participant has residual bladder volume less than 150cc in Post-void Residual Volume Measurement test.
  • •8. Participant is able and willing to comply with the protocol and follow-up.
  • •9. Participant is fluent in the English language.
  • •10. Participant is able to provide written informed consent.

Exclusion Criteria

  • •Participants in this study must not meet any of the following exclusion criteria, as determined by the Investigator:
  • •1. Participant has a primary diagnosis of stress incontinence (or mixed incontinence where the stress component overrides the urgency component)
  • •2. Participant has a concomitant diagnosis of neurogenic bladder.
  • •3. Participant has a concomitant diagnosis of interstitial cystitis or bladder pain syndrome.
  • •4. Participant has a pain complaint that forms a major component of their symptomatology which, in the opinion of the investigator, may confound reporting of OAB symptoms.
  • •5. Participant has a urinary tract obstruction or urethral stricture.
  • •6. Participant has a history of pelvic radiation or ongoing pelvic cancer.
  • •7. Participant has a medical condition that could interfere with study procedures, accurate bladder function reporting and/or confound evaluation of study endpoints, as determined by the Investigator.
  • •8. Participant has evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of disease, compliance with intervention and/or ability to evaluate treatment outcomes.
  • •9. Participant has a diagnosis of an uncontrolled coagulation disorder, bleeding diathesis, or progressive peripheral vascular disease.
  • •10. Participant has a diagnosis of type I or type II diabetes requiring insulin therapy.
  • •11. Participant has previously failed an SNS therapy trial or had a full SNS system implanted.
  • •12. Participant has an implanted pacemaker and/or another active implanted medical device that may interfere with the Repose SNS system.
  • •13. In the previous 9 months, the participant has been treated with botulinum toxin injection for their OAB symptoms.
  • •14. In the previous 3 months, the participant has been treated with tibial nerve stimulation for their OAB symptoms.
  • •15. Participant has a condition currently requiring or likely to require the use of MRI, or high output ultrasound.
  • •16. Participant has a life expectancy of less than 2 years.
  • •17. Participant has a symptomatic, active systemic infection or local infection including an active urinary tract infection (UTI), or has had more than three culture-proven UTI’s in the previous 12 months.
  • •18. Participant is allergic or has shown hypersensitivity to ethylene oxide or any materials of the neurostimulation system which come in contact with the body.
  • •19. Participant is pregnant or nursing (requires negative pregnancy test for women of childbearing potential). If female and sexually active, participant must be using a reliable form of birth control, be surgically sterile or be at least 2 years post-menopausal.
  • •20. Within 6 months of enrolment, participant has had a significant untreated addiction to dependency-producing medications or has been a substance abuser (including alcohol and/or illicit drugs).
  • •21. Participant is concomitantly participating in another clinical study, unless pre-approved by the Sponsor.
  • •22. Participant is involved in an injury claim under current litigation in which relief of their OAB symptoms may be considered detrimental (i.e. secondary gains).

Investigators

Sponsor
Closed Loop Medical Pty Ltd

Similar Trials

Completed
Not Applicable
Study to Evaluate the Safety and Efficacy of Levetiracetam in Comparison To Magnesium Sulphate in the Management of Severe Pre â?? Eclampsia
CTRI/2020/02/023194BLDE Deemed to be University30
Not yet recruiting
Phase 4
To study the Safety and Efficacy of Investigational Hair oil in comparison with coconut oil and comparator Hair oil in subjects with mild to severe Hair fall
CTRI/2020/04/024824Thai Herbals
Completed
Phase 4
Study to evaluate the Safety and Efficacy of Investigational Hair Oil in comparison with Coconut oil and Comparator Hair Oil in subjects with mild to severe Hair fall.
CTRI/2018/05/014260Dhathri Ayurveda Pvt Ltd40
Completed
Phase 4
the study Safety and Efficacy of Anti-Hair fall shampoo in comparison with Comparator Anti-Hair fall shampoo in subjects with very less to severe Hair fall
CTRI/2018/06/014444Dhathri Ayurveda Pvt Ltd40
Completed
Phase 4
To evaluate the Safety and Efficacy of Investigational Hair creme in comparison with coconut oil in subjects with mild to severe Hair fall
CTRI/2018/06/014418Dhathri Ayurveda Pvt Ltd40